Eli Lilly Inks Deal With Nimbus Therapeutics To Find New Obesity Drug With AI
Under the deal, Nimbus is eligible to receive up to $1.3 billion.
Nimbus Therapeutics on Tuesday said that it has entered into a multi-year agreement with drugmaker Eli Lilly & Co to develop a new oral treatment for obesity and other metabolic diseases.
Privately held Nimbus and Lilly have previously collaborated to develop drugs for certain cardiometabolic diseases. They will now apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery program, the company said.
Under the deal, Nimbus is eligible to receive upfront and near-term milestone payments totaling $55 million. This could scale to $1.3 billion in total including development, commercial, and sales milestone payments, as well as tiered royalties on global net sales, the company added.
Get updates to this developing story directly on Stocktwits.
